Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-24T06:54:30.682Z Has data issue: false hasContentIssue false
  • English
  • Français

The diagnostic value of plasma N-terminal connective tissue growth factor levels in children with heart failure

Published online by Cambridge University Press:  16 March 2016

Gang Li ,
Xueqing Song ,
Jiyi Xia ,
Jing Li ,
Peng Jia ,
Pengyuan Chen ,
Jian Zhao  and
Bin Liu
Gang Li
Affiliation:
Department of Pediatrics, The Affiliated Hospital of Sichuan Medical University, Sichuan, China
Xueqing Song
Affiliation:
Medical Research Center, The Affiliated Hospital of Sichuan Medical University, Sichuan, China
Jiyi Xia
Affiliation:
Research Center for Drug and Functional Foods of Sichuan Medical University, Sichuan, China
Jing Li
Affiliation:
Department of Emergency, The Affiliated Hospital of Sichuan Medical University, Sichuan, China
Peng Jia
Affiliation:
Department of Pediatrics, The Affiliated Hospital of Sichuan Medical University, Sichuan, China
Pengyuan Chen
Affiliation:
Department of Pediatrics, Sichuan Provincial People’s Hospital, Sichuan, China
Jian Zhao
Affiliation:
Department of Pediatrics, The Affiliated Hospital of Sichuan Medical University, Sichuan, China
Bin Liu*
Affiliation:
Department of Pediatrics, The Affiliated Hospital of Sichuan Medical University, Sichuan, China
*
Correspondence to: B. Liu, Department of Pediatrics, The Affiliated Hospital of Sichuan Medical University, No. 25, Taiping Street, Luzhou, 646000, Sichuan, China. Tel: +86 830 3165613; Fax: +86 830 3163899; E-mail: lblyfy@126.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

The aim of this study was to assess the diagnostic value of plasma N-terminal connective tissue growth factor in children with heart failure.

Methods and results

Plasma N-terminal connective tissue growth factor was determined in 61 children, including 41 children with heart failure, 20 children without heart failure, and 30 healthy volunteers. The correlations between plasma N-terminal connective tissue growth factor levels and clinical parameters were investigated. Moreover, the diagnostic value of N-terminal connective tissue growth factor levels was evaluated. Compared with healthy volunteers and children without heart failure, plasma N-terminal connective tissue growth factor levels were significantly elevated in those with heart failure (p<0.01). N-terminal pro-brain natriuretic peptide and left ventricular end-diastolic dimension were positively correlated with plasma N-terminal connective tissue growth factor levels (r=0.364, p=0.006; r=0.308, p=0.016), whereas there was a negative correlation between left ventricular ejection fraction and plasma N-terminal connective tissue growth factor (r=−0.353, p=0.005). Connective tissue growth factor was significantly correlated with the severity of heart failure (p<0.001). Moreover, addition of connective tissue growth factor to N-terminal pro-brain natriuretic peptide did not significantly increase area under curve for diagnosing heart failure (area under curve difference 0.031, p>0.05), but it obviously improved the ability of diagnosing heart failure in children, as demonstrated by the integrated discrimination improvement (6.2%, p=0.013) and net re-classification improvement (13.2%, p=0.017) indices.

Conclusions

Plasma N-terminal connective tissue growth factor is a promising diagnostic biomarker for heart failure in children.

Keywords

Connective tissue growth factorheart failureN-terminal pro-brain natriuretic peptidebiomarkerchildren
Type
Original Articles
Information
Cardiology in the Young , Volume 27 , Issue 1 , January 2017 , pp. 101 - 108
Check for updates
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Rossano, JW, Jang, GY. Pediatric heart failure: current state and future possibilities. Korean Circ J 2015; 45: 1–8.CrossRefGoogle ScholarPubMed
2. Fiuzat, M, O’Connor, CM, Gueyffier, F, et al. Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail 2013; 19: 592–599.CrossRefGoogle ScholarPubMed
3. Gruson, D, Ahn, SA, Rousseau, MF. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure. Peptides 2015; 64: 24–28.CrossRefGoogle ScholarPubMed
4. Cohen, S, Springer, C, Avital, A, et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress. Pediatrics 2005; 115: 1347–1350.CrossRefGoogle ScholarPubMed
5. Nir, A, Bar-Oz, B, Perles, Z, Brooks, R, Korach, A, Rein, AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004; 93: 603–607.CrossRefGoogle ScholarPubMed
6. Nir, A, Nasser, N. Clinical value of NT-proBNP and BNP in pediatric cardiology. J Card Fail 2005; 11: S76–S80.CrossRefGoogle ScholarPubMed
7. Zhang, SR, Zhang, YH, Xu, Q, Qiu, HX, Chen, Q. Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with CHD. Zhongguo Dang Dai Er Ke Za Zhi 2009; 11: 429–432.Google Scholar
8. Bradham, DM, Igarashi, A, Potter, RL, Grotendorst, GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991; 114: 1285–1294.CrossRefGoogle Scholar
9. Chen, L, Charrier, A, Zhou, Y, et al. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2014; 59: 1118–1129.CrossRefGoogle ScholarPubMed
10. Klaassen, I, van Geest, RJ, Kuiper, EJ, van Noorden, CJ, Schlingemann, RO. The role of CTGF in diabetic retinopathy. Exp Eye Res 2015; 133: 37–48.CrossRefGoogle ScholarPubMed
11. Wu, CK, Wang, YC, Lee, JK, et al. Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan diastolic heart failure registry and molecular basis by cellular and animal models. Eur J Heart Fail 2014; 16: 163–172.CrossRefGoogle ScholarPubMed
12. Dziadzio, M, Usinger, W, Leask, A, et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM 2005; 98: 485–492.CrossRefGoogle ScholarPubMed
13. Koitabashi, N, Arai, M, Niwano, K, et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 373–379.CrossRefGoogle ScholarPubMed
14. Bergestuen, DS, Gravning, J, Haugaa, KH, et al. Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. BMC Cancer 2010; 10: 6.CrossRefGoogle ScholarPubMed
15. Behnes, M, Brueckmann, M, Lang, S, et al. Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure. Clin Res Cardiol 2014; 103: 107–116.CrossRefGoogle ScholarPubMed
16. Miyazaki, O, Kurashita, S, Fukamachi, I, Endo, K, Ng, PS, Takehara, K. Subtraction method for determination of N-terminal connective tissue growth factor. Ann Clin Biochem 2010; 47: 205–211.CrossRefGoogle ScholarPubMed
17. Ross, RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol 2012; 33: 1295–1300.CrossRefGoogle Scholar
18. Lopez, L, Colan, SD, Frommelt, PC, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 2010; 23: 465–495; quiz 576–577.CrossRefGoogle ScholarPubMed
19. Cicha, I, Garlichs, CD, Daniel, WG, Goppelt-Struebe, M. Activated human platelets release connective tissue growth factor. Thromb Haemost 2004; 91: 755–760.CrossRefGoogle ScholarPubMed
20. Kato, M, Fujisawa, T, Hashimoto, D, et al. Plasma connective tissue growth factor levels as potential biomarkers of airway obstruction in patients with asthma. Ann Allergy Asthma Immunol 2014; 113: 295–300.CrossRefGoogle ScholarPubMed
21. Hanley, JA, McNeil, BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839–843.CrossRefGoogle ScholarPubMed
22. Pencina, MJ, D’Agostino, RB Sr, D’Agostino, RB Jr, Vasan, RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172; discussion 207–212.CrossRefGoogle ScholarPubMed
23. Chuva de Sousa Lopes, SM, Feijen, A, Korving, J, et al. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn 2004; 231: 542–550.CrossRefGoogle ScholarPubMed
24. Ahmed, MS, Øie, E, Vinge, LE, et al. Connective tissue growth factor – a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 2004; 36: 393–404.CrossRefGoogle ScholarPubMed
25. Koitabashi, N, Arai, M, Kogure, S, et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007; 49: 1120–1127.CrossRefGoogle ScholarPubMed
26. Tsoutsman, T, Wang, X, Garchow, K, Riser, B, Twigg, S, Semsarian, C. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J Mol Cell Cardiol 2013; 62: 164–178.CrossRefGoogle Scholar
27. Blom, IE, Goldschmeding, R, Leask, A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy. Matrix Biol 2002; 21: 473–482.CrossRefGoogle ScholarPubMed
28. Sahin, M, Portakal, O, Karagöz, T, Hasçelik, G, Özkutlu, S. Diagnostic performance of BNP and NT-proBNP measurements in children with heart failure based on congenital heart defects and cardiomyopathies. Clin Biochem 2010; 43: 1278–1281.CrossRefGoogle ScholarPubMed
29. Gravning, J, Ahmed, MS, von Lueder, TG, Edvardsen, T, Attramadal, H. CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressure-overload. Int J Cardiol 2013; 168: 2049–2056.CrossRefGoogle ScholarPubMed
30. Gravning, J, Ørn, S, Kaasbøll, OJ, et al. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction. PLoS One 2012; 7: e52120.CrossRefGoogle ScholarPubMed
31. Braunwald, E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148–2159.CrossRefGoogle ScholarPubMed
32. Hayata, N, Fujio, Y, Yamamoto, Y, et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008; 370: 274–278.CrossRefGoogle ScholarPubMed
33. Jungbauer, CG, Riedlinger, J, Block, D, et al. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark Med 2014; 8: 777–789.CrossRefGoogle ScholarPubMed
34. Bielecka-Dabrowa, A, Gluba-Brzózka, A, Michalska-Kasiczak, M, Misztal, M, Rysz, J, Banach, M. The multi-biomarker approach for heart failure in patients with hypertension. Int J Mol Sci 2015; 16: 10715–10733.CrossRefGoogle ScholarPubMed